의약품 분야의 라이선싱 계약(2020-2026년)

Benchmark Licensing Partnerships Across the Global Pharmaceutical Industry

Request our free report sample

The Licensing Deals in Pharmaceuticals 2020-2026 report provides a comprehensive analysis of licensing agreements across the global pharmaceutical industry. Designed for business development, licensing, legal, and strategy professionals, the report delivers detailed insight into how companies structure licensing partnerships, negotiate financial terms, and allocate development and commercialization rights.

Fully revised and updated, the report includes details of more than 2,700 licensing deals announced between 2020 and 2026, providing an extensive view of licensing activity across the pharmaceutical sector. Each deal record includes financial terms where available and links to online deal records and contract documents filed with regulators when publicly disclosed.

By combining detailed deal data, financial benchmarking, and access to real contract documents, the report provides valuable intelligence for evaluating potential partners, structuring licensing agreements, and negotiating stronger deal terms.

Key Benefits

• Save Significant Research Time

Access over 2,700 licensing deals in a single resource, eliminating the need to search multiple databases, press releases, and regulatory filings.

• Benchmark Licensing Deal Structures

Understand how pharmaceutical companies structure licensing partnerships, including development responsibilities, territorial rights, and commercialization arrangements.

• Analyze Financial Terms with Confidence

Review disclosed payment structures such as upfront payments, milestone payments, and royalties, enabling accurate benchmarking of licensing deal value.

• Access Real Contract Documents

Where available, explore actual licensing agreements filed with the SEC, providing deeper insight into the contractual provisions behind real-world deals.

• Identify Active Licensing Dealmakers

Discover which companies are most active in pharmaceutical licensing and analyze their partnership strategies.

• Track Licensing Trends

Analyze licensing activity since 2020 across companies, therapeutic areas, and technologies to understand how industry partnering strategies are evolving.

What's Included in the Report

Analysis of pharmaceutical licensing dealmaking trends since 2020

Overview of licensing deal structures and financial models

Review of leading licensing deals by disclosed value

Profiles of the most active licensing dealmakers

Detailed analysis of deals by company, therapeutic area, and technology type

A comprehensive deal directory covering all licensing deals announced since 2020

Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

By reviewing actual licensing contracts, the report allows users to evaluate key partnership provisions such as:

• Rights granted or optioned under the license
• Upfront payments, milestone payments, and royalty structures
• Intellectual property ownership and licensing scope
• Development, manufacturing, and commercialization responsibilities
• Exclusivity provisions and territorial rights
• Contract duration and termination provisions
• Why This Report Matters
• Licensing agreements are a cornerstone of pharmaceutical innovation, enabling companies to access new technologies, share development risk, and accelerate product commercialization.
• By providing comprehensive deal data, financial benchmarking, and access to real contract documents, this report delivers the intelligence needed to structure stronger licensing partnerships and negotiate more effectively.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

• 2.1. Introduction
• 2.2. Definition of licensing deal
• 2.3. Trends in licensing deals since 2020
  • 2.3.1. Licensing dealmaking by year
  • 2.3.2. Licensing dealmaking by phase of development
  • 2.3.3. Licensing dealmaking by industry sector
  • 2.3.4. Licensing dealmaking by therapy area
  • 2.3.5. Licensing dealmaking by technology type
  • 2.3.6. Licensing dealmaking by most active company
• 2.4. Reasons for entering into licensing partnering deals
• 2.5. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

• 3.1. Introduction
• 3.2. Licensing agreement structure

Chapter 4 - Leading licensing deals

• 4.1. Introduction
• 4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deals including contracts directory

• 6.1. Introduction
• 6.2. Licensing deals with contracts
• Deal directory
• Deal directory - licensing dealmaking by companies A-Z
• Deal directory - licensing dealmaking by therapy area
• Deal directory - licensing dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of licensing
• Figure 2: Trends in licensing deal announcements
• Figure 3: Licensing deals signed at each phase of development
• Figure 4: Licensing deals by industry sector
• Figure 5: Licensing deals by therapy area
• Figure 6: Licensing deals by technology type
• Figure 7: Top 25 most active licensing dealmakers
• Figure 8: Top licensing deals by value
• Figure 9: Most active licensing dealmakers